By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later ...

Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe’s most valuable public company again. Now, the stock ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

President Donald Trump's new European tariffs could significantly increase the cost of Novo Nordisk's weight loss drug, Ozempic.

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

HYDERABAD — Dr Reddy’s Laboratories is gearing up to enter the booming global obesity drug market with a more affordable ...